The FDA has expanded the approval of blinatumomab (Blincyto) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults and children.
Acute Lymphoblastic Leukemia
Adult patients with early thymic precursor (ETP) acute lymphoblastic leukemia (ALL), a subgroup of T-cell ALL, could benefit from the use of response-based risk stratification and therapy intensification similar to that used in pediatric patients with ETP-ALL.
There is considerable value in having achieved a minimal residual disease negativity for pediatric and adult patients with acute lymphoblastic leukemia.
Female survivors of childhood acute lymphoblastic leukemia were at risk for neurocognitive impairment and were more susceptible to the effects of sleep disturbance and fatigue compared with their male counterparts.
Single-agent use of blinatumomab resulted in anti-leukemic activity in patients with tyrosine kinase inhibitor–relapsed or refractory Philadelphia chromosome positive B-precursor acute lymphoblastic leukemia.
Low pretreatment disease burden improved durability of CAR T-cell therapy in patients with relapsed B-cell acute lymphoblastic leukemia.
During maintenance therapy for childhood ALL, there was a general increase in DNA-incorporated thioguanine nucleotides (DNA-TGN), and this increase was associated with a lower frequency of disease relapse.
Presentation with musculoskeletal manifestations as the only symptom in pediatric B-cell acute lymphoblastic leukemia was significantly associated with diagnostic delay. However, this delay did not affect patient prognosis.
The use of minimal residual disease provided a more objective measure of induction failure in patients with pediatric acute lymphoblastic leukemia than did morphology.
In this article we discuss the challenges and new advances in adult ALL, as well as our approach to the treatment of these patients.